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Abstract
Background: Non-Shiga toxin-associated hemolytic uremic syndrome is known to be caused by dysregulation of
the alternative complement pathway. Infections, drugs, pregnancy, bone marrow transplantation, malignancy, and
autoimmune disorders have all been reported to trigger episodes of atypical hemolytic uremic syndrome. To the
best of our knowledge, there have been no previous reports of an association between diabetic ketoacidosis and
atypical hemolytic uremic syndrome.
Case presentation: We describe a case of a 26-year-old Spanish man who presented with diabetic ketoacidosis
and was found to have the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney
injury. The patient had a normal ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1
motif, member 13) activity level, and his renal biopsy demonstrated predominant changes of diabetic
glomerulosclerosis with an area compatible with thrombotic microangiopathy suggestive of superimposed atypical
hemolytic uremic syndrome. Complement sequencing subsequently revealed a potential causative mutation in
exon 12 of complement factor B with changes of lysine at amino acid position 533 to an arginine (CFB p.K533R).
Conclusions: To the best of our knowledge, this is the first case report of diabetic ketoacidosis presenting with
atypical hemolytic uremic syndrome associated with a variant of complement factor B in an adult patient.
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Background
Hemolytic uremic syndrome (HUS) is characterized by
the triad of microangiopathic hemolytic anemia,
thrombocytopenia, and acute kidney injury. The majority
of the cases are seen in childhood and are caused by
Shiga-like toxin (so-called typical HUS). Non-Shiga
toxin-associated HUS (atypical HUS, or aHUS) is known
to be caused by dysregulation of the alternative comple-
ment pathway due to genetic mutations or neutralizing
autoantibodies [1]. Infections, drugs, pregnancy, bone
marrow transplantation, malignancy, and autoimmune
disorders have all been reported to trigger episodes of
aHUS [1]. To the best of our knowledge, there have been
no reports of an association between diabetic ketoacido-
sis (DKA) and aHUS. We report a case of an adult
patient with DKA presenting with aHUS associated with
a variant of complement factor B (CFB).
Case presentation
A 26-year-old Hispanic man with a history of type 1 dia-
betes that had been diagnosed between 12 and 14 years
of age was brought to the emergency department (ED)
after two episodes of new-onset seizures at home. A
family member reported that the patient had stopped
taking insulin for 1 day before presentation. He com-
plained of epigastric pain and nonbloody, nonbilious
vomiting at home. In the ED, the patient had another
two episodes of tonic-clonic seizures.
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His physical examination revealed that he was agitated,
febrile (body temperature 38.5 °C), hypertensive (blood
pressure 149/87 mmHg), and tachycardiac (heart rate
105 beats/minute). The remainder of his physical exam-
ination was unremarkable. His laboratory data (Table 1)
were remarkable for hyperglycemia and high anion gap
metabolic acidosis with an elevated β-hydroxybutyrate
level compatible with DKA. No central nervous system
pathology was revealed by a computed tomographic scan
of his brain without intravenous contrast or by a lumbar
puncture. The patient was admitted to the intensive care
unit for management of DKA. His ketoacidosis resolved
within 24 hours on intravenous fluids and an insulin
drip. However, he continued to remain very drowsy in
spite of correction of the DKA. Repeat laboratory data
showed anemia (hemoglobin 9.1 g/dl, baseline value
11.8 g/dl 2 months prior), thrombocytopenia (150 ×
109/L, baseline value 416 × 109/L 2 months prior),
acute kidney injury with a blood urea nitrogen/cre-
atinine ratio of 33/3.4 mg/dl (baseline value 40/1.4
mg/dl 2 months prior), and evidence of hemolysis (lac-
tate dehydrogenase 1700 IU/L, indirect bilirubin 1.7
mg/dl) with schistocytes present on his peripheral
blood smear. His presentation strongly suggested the
possibility of thrombotic thrombocytopenic purpura/
HUS, and emergent, empiric plasmapheresis was initi-
ated while awaiting the result for the ADAMTS13 (a
disintegrin and metalloproteinase with a thrombos-
pondin type 1 motif, member 13) activity level. His
additional serologic workup results, including comple-
ment components C3 and C4, antinuclear antibodies,
antineutrophil cytoplasmic antibodies, cryoglobulins,
anti-glomerular basement membrane antibody, and
hepatitis B and C panels, were normal or negative.
The patient responded with a dramatic improvement in
mental status and hemolytic parameters after 5 days of
plasmapheresis (Table 1). Unfortunately, his kidney func-
tion did not improve. On day 6, his ADAMTS13 activity
was reported as normal (81 %, reference range 68–163 %
activity). His anti-complement factor H (anti-CFH) anti-
body result was negative. His renal biopsy showed moder-
ate to severe nodular diabetic glomerulosclerosis with
superimposed thrombotic microangiopathy in a single
glomerulus, suggestive of superimposed aHUS (Fig. 1).
Complement sequencing of the coding regions of CFH,
complement factor I (CFI), CFB, C3, membrane cofactor
protein (MCP, CD46), diacylglycerol kinase ε, and throm-
bomodulin was completed. A heterozygous, nonsynon-
ymous variant was identified in exon 12 of CFB with
changes of a lysine at amino acid position 533 to an argin-
ine (CFB p.K533R). The patient was started on treatment
with eculizumab, a humanized monoclonal antibody tar-
geting complement component C5, after he received men-
ingococcal vaccine. He had no further episode of DKA or
aHUS during 5 months of follow-up after initiation of
eculizumab therapy. However, his renal function gradually
deteriorated and hemodialysis was started (Table 1, Fig. 2).
He is currently being evaluated for kidney transplant.
Discussion
Extensive research has established an association be-
tween aHUS and the alternative complement pathway. It
has been reported that mutations in the genes encoding
proteins regulating the alternative complement pathway
may result in abnormal activation of this pathway. It
could be due to loss-of-function mutations in CFH,
MCP, and CFI by either nonsense or missense mutations
or by gain-of-function mutations in C3 and CFB [1].
Under normal circumstances, the CFB gene encodes the
factor B protein, which is a component of C3 convertase,
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ADAMTS13 a disintegrin and metalloproteinase with a thrombospondin type 1
motif, member 13, BUN blood urea nitrogen, Hb hemoglobin, HPF high-power
field, LDH lactate dehydrogenase, RBC red blood cells, WBC white blood cells
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C3bBb, and catalyzes the proteolytic cleavage of C3 into
C3a and C3b. Genetic mutations in the CFB gene may
cause either enhanced formation of C3 convertase or
increase its resistance to inactivation, thus leading to
uncontrolled hyperactivity of the alternative complement
pathway. CFB mutations have previously been reported to
be associated with aHUS at a frequency as high as 1.4 %
[2]. Table 2 lists all the previously reported cases with CFB
mutations in patients with aHUS; the majority of these re-
ported patients were children. The first two mutations in
CFB gene F286L in exon 6 and K323E in exon 7 are both
gain-of-function mutations that enhance the formation of
C3 convertase [3, 4]. The CFB mutation (p.Lys350Asn)
reported by Funato and colleagues causes resistance to
decay acceleration factor and therefore increases C3bBb
stability [5].
Regarding our patient with adult-onset aHUS, we report
the p.K533R mutation in exon 12 of CFB with change of a
lysine at amino acid position 533 to an arginine. This muta-
tion was previously identified in an 8-year-girl with aHUS
reported by Tawadrous and colleagues [4], who believed it
to contribute to the pathogenesis of aHUS. Further evi-
dence in favor of the potentially pathogenic effect is the
fairly rare minor allele frequency of 0.2 % in the Latino
population, in which aHUS is a rare event [6]. More
recently, Marinozzi and colleagues [7] performed compre-
hensive assessment of the p.K508R mutation, a more
Fig. 1 Kidney biopsy showed (a) moderate to marked, diffuse, and global increase in mesangial matrix-forming nodules compressing the capillary
lumina and (b) only one glomerulus containing a fibrin thrombus involving the hilar region of the tuft
Fig. 2 Serum creatinine changes during the course of hospitalization
and follow-up. DKA diabetic ketoacidosis, ESRD end-stage renal disease,
HD hemodialysis, TMA thrombotic microangiopathy
Table 2 Previously reported CFB mutations in patients with
atypical hemolytic uremic syndrome reported in the
English-language literature
Case reports Sex Age Mutation; amino acid change
Fremeaus-Bacchi
et al. [2]
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mature protein of p.K533R after removing the leader pep-
tide, which leads to altered numbering for the same variant.
They concluded that p.K508R most likely represents a rare
benign polymorphism. Although they acknowledged that
the p.K508R variant did confer moderately increased serine
protease activity in vitro, they judged it as inadequate to
explain the reduction of C3 clinically. On the basis of the
American College of Medical Genetics and Genomics
standards [8], current understanding of the clinical
interpretation for this variant is that it is “a variant of
uncertain clinical significance.” However, controver-
sies still exist. Therefore, additional studies are re-
quired for further clarification of the contribution of
this rare variant/polymorphism to the pathogenesis of
aHUS. In addition, with new technology, more genetic
mutations that contribute to the pathogenesis of aHUS
are likely to be identified in the future [9–11]. There-
fore, we speculate that the combination of multiple
incompletely penetrant variants or a “trigger event”
may contribute to the development of aHUS in some
cases such as our patient’s.
It has been proposed that a “trigger event” or a “second
hit” is related to precipitation of an episode of aHUS in a
susceptible individual. These individuals may have gene
mutations or antibodies to complement proteins that lead
to uncontrolled continuous activation of the alternative
pathway, resulting in the formation of the membrane
attack complex. Various trigger events associated with
aHUS have been reported previously, including infections,
drugs, malignancy, pregnancy, or autoimmune diseases
such as systemic lupus erythematous, C3 nephritic factor,
and anticardiolipin. No obvious infectious etiology was
identified in our patient. He was noncompliant with
insulin therapy, which may lead to development of DKA.
Subsequently, DKA may have been the “trigger event” for
the episode of aHUS due to genetic predisposition with
the CFB p.K533R variant. However, the possibility that
aHUS may have precipitated DKA in our patient cannot
be completely ruled out. Studies have shown that
hemostatic changes leading to a thrombotic tendency
occur during ketoacidosis [12, 13]. In addition, DKA
elicits systemic inflammation associated with dysregu-
lation of adhesion molecule expression and cytokine
release by endothelial cells [14]. We propose that, in
our patient, endothelial cell dysfunction during DKA
enhanced the abnormality of endothelial damage and
microvascular thrombosis mediated by his abnormal
complement activity and further activated the comple-
ment pathway, leading to his aHUS episode.
Treatment of aHUS has been evolving rapidly with the
recent approval of eculizumab, a humanized monoclonal
antibody that binds with high affinity to the human C5
protein [15, 16]. End-stage renal disease or death was
reported to occur in up to 65 % of patients with aHUS
before eculizumab was introduced [17]. Eculizumab has
been reported to be effective, with improvement of renal
function as well as decreased episodes of aHUS. Our
patient’s kidney function gradually worsened despite
eculizumab therapy, which was likely secondary to pro-
gression of diabetic nephropathy because only a small
area of superimposed thrombotic microangiopathy (TMA)
was identified together with moderate to severe nodular
diabetic glomerulosclerosis in the kidney biopsy and no
further episode of aHUS has occurred since then. He was
started on hemodialysis and currently is awaiting evalu-
ation for kidney transplant. The patient will require
standard maintenance treatment with lifelong eculizumab
because only very limited evidence regarding discontinu-
ation of eculizumab has been reported to date [18].
Conclusions
To the best of our knowledge, we report the first case of
DKA presenting with aHUS in an adult patient. We re-
port a potential causative mutation for aHUS: p.K533R
in exon 12 of CFB.
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